文献速递鼻科咽喉与嗓音

Tezepelumab治疗哮喘合并鼻息肉患者的上下气道应答:6个月真实世界观察

Upper and lower airways response to tezepelumab in asthma patients with / without comorbid nasal polyposis: a 6-months reallife perspective.
PubMed 文献 · Rhinology · 2026-01-01

本研究回顾性分析5家转诊中心的数据,评估tezepelumab治疗重度哮喘合并或不合并CRSwNP患者在6个月内的鼻部与支气管结局,发现鼻部结局及哮喘相关参数均快速显著改善,且无论有无CRSwNP治疗应答无差异。

要点

  • tezepelumab可快速显著改善重度哮喘合并CRSwNP患者的鼻部结局。
  • 无论有无CRSwNP,tezepelumab对哮喘相关参数的改善无差异。
  • tezepelumab可减少口服激素使用、住院和急性发作。

核心结论

  • 在真实世界中,tezepelumab可快速持续改善重度哮喘合并CRSwNP患者的鼻部结局及哮喘临床参数,且不受上气道共病影响。

研究设计与样本

  • 回顾性分析5家重度哮喘与CRSwNP转诊中心的数据,评估tezepelumab起始后基线、3个月和6个月的结局。

主要发现

  • tezepelumab显著且快速改善所有鼻部结局和哮喘相关参数,不受性别、体重指数、既往生物制剂使用或病程影响。
  • 观察到口服糖皮质激素使用、住院和急性发作显著减少。
  • 合并与不合并CRSwNP的患者在治疗应答方面无差异。

关键数值与推荐

  • 鼻部评估包括SNOT-22、VAS和鼻息肉评分,支气管评估包括哮喘控制测试和肺功能。

临床怎么用

  • tezepelumab可用于重度哮喘合并CRSwNP患者的真实世界治疗,以精准医学方式定位。

局限性

  • 需要更大规模的研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUD: The efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP) has been demonstrated in clinical trials, but real-world evidence remains limited. Our study investigated the trend of CRSwNP outcomes in patients prescribed with tezepelumab for severe asthma and the impact of upper airways comorbidity on asthma outcomes over a 6 months follow-up. METHODS: Data from 5 referral centres for severe asthma and CRSwNP were retrospectively analysed. Patient reported outcomes and objective measures related to nasal (SNOT-22, VAS, nasal polyp score) and bronchial (asthma control test, lung function) evaluation were assessed at baseline, 3 and 6 months after tezepelumab initiation. RESULTS: Tezepelumab significantly and rapidly improved all the nasal outcomes and asthma-related parameters, irrespective of sex, body mass index, prior biologic use, or disease duration. Furthermore, significant reduction of oral corticosteroid use, hospitalizations and exacerbations were also observed. When comparing patients with and without CRSwNP, no differences were observed in term of treatment response. CONCLUSIONS: In patients with severe asthma and CRSwNP, tezepelumab demonstrated to induce in the real-life setting an overall rapid and sustained improvement of nasal outcomes, as well as of lung function and clinical parameters in asthma patients regardless of upper airway involvement. Although larger studies are needed, these findings contribute to the positioning of tezepelumab in the real-world clinical practice according to a precision medicine approach.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Caminati M, Mastrototaro A, Maule M, et al. Upper and lower airways response to tezepelumab in asthma patients with / without comorbid nasal polyposis: a 6-months reallife perspective. Rhinology. 2026. PMID: 41521892. doi:10.4193/Rhin25.474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。